[
  {
    "ts": null,
    "headline": "Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals",
    "summary": "INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.",
    "url": "https://finnhub.io/api/news?id=dfe1131200fe7662acfb6c876ee2b312999e245e15a8d565b3be053f63505200",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733768040,
      "headline": "Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals",
      "id": 131898537,
      "image": "https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.",
      "url": "https://finnhub.io/api/news?id=dfe1131200fe7662acfb6c876ee2b312999e245e15a8d565b3be053f63505200"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corp. stock underperforms Monday when compared to competitors",
    "summary": "Incyte Corp. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=553fb40f6d475f6470300e5d5bc99f22b37e141645cba7e017ef007bf7021b0b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733764500,
      "headline": "Incyte Corp. stock underperforms Monday when compared to competitors",
      "id": 131892637,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=553fb40f6d475f6470300e5d5bc99f22b37e141645cba7e017ef007bf7021b0b"
    }
  },
  {
    "ts": null,
    "headline": "EXEL or INCY: Which Is the Better Value Stock Right Now?",
    "summary": "EXEL vs. INCY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=28cb07a7377830cfc4b877a4833ad47cc135498b071fab9ef1ed21a51e282935",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733762410,
      "headline": "EXEL or INCY: Which Is the Better Value Stock Right Now?",
      "id": 131898538,
      "image": "https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "EXEL vs. INCY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=28cb07a7377830cfc4b877a4833ad47cc135498b071fab9ef1ed21a51e282935"
    }
  }
]